DPP4 and COVID-19: Regarding outcomes, COVID-19 mortality was significantly lower in the DPP-4 inhibitor group (4.3%) compared to the non-DPP-4 inhibitor group (10.3%) The oxygen application rates were 26.9% in the DPP-4 inhibitor group and 25.0% in the non-DPP-4 inhibitor group, with no statistically significant difference.